CD70 expression in initially diagnosed diffuse large B cell lymphoma and its clinical significance
Objective To analyze the expression of CD70 in diffuse large B cell lymphoma(DLBCL)and its corre-lation with clinical prognosis.Methods A total of 116 patients newly diagnosed with DLBCL who were admitted to the First Affiliated Hospital of Bengbu Medical College from January 2017 to December 2021 were selected and their clinical data were retrospectively analyzed.The expression of CD70 in tumor tissues was detected,and the clinical significance of CD70 expression in DLBCL patients was analyzed.Results The positive expression rate of CD70 in 116 DLBCL patients was 80.17%,and its expression was related to mid-term efficacy,B symptoms,bone marrow involvement and Ann Ar-bor stage(P＜0.05).However,CD70 expression was not associated with sex,age,lactate dehydrogenase(LDH),β2-microglobulin(β2-MG),B-cell lymphoma-2(BCL-2),BCL-6,Ki-67,Hans classification,primary site and inter-national prognostic index(IPI)score(P＞0.05).Survival analysis showed that the progression free survival(PFS)and overall survival(OS)of the CD70 positive group were significantly higher than those in the CD70 negative group(P＜0.05),and the prognosis of CD70 positive patients was worse.According to univariate analysis,the prognosis of DLBCL patients was affected by efficacy,LDH,β2-MG,Ki-67,Hans classification,Ann Arbor stage,IPI score and CD70 ex-pression.Multivariate analysis showed that mid-term efficacy,Ki-67,Hans classification and CD70 were the independ-ent prognostic factors for PFS,and mid-term efficacy,β2-MG、Ki-67、Hans subtype and CD70 were the independent prognostic factors for OS.Conclusions CD70 is highly expressed in DLBCL and strongly associated with poor prognosis.
CD70diffuse large B-cell lymphomaprognosisprogression free survivaloverall survival
NETL
NSTL
万方数据
维普
